John Chapman
Surgical · Houston, TXNPI 1184268617
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 709 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Viiv Healthcare Company at 33.0% of the total. Among surgical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 709 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$5K
- Gilead$3K
- Theratechnologies Inc.$1K
- Napo Pharmaceuticals Inc$897
- Novo Nordisk$882
- Merck$772
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$570%
- Food & beverage$14,962100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 223 | $4,957 |
| Gilead | 151 | $3,423 |
| Theratechnologies Inc. | 51 | $1,189 |
| Napo Pharmaceuticals Inc | 47 | $897 |
| Novo Nordisk | 55 | $882 |
| Merck | 36 | $772 |
| EMD Serono, Inc. | 18 | $429 |
| Lilly USA, LLC | 17 | $366 |
| Antares Pharma, Inc. | 20 | $351 |
| AstraZeneca | 14 | $319 |
| Amgen | 17 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $214 |
| Johnson & Johnson(2 entities) | 10 | $167 |
| Amarin Pharma, Inc. | 8 | $138 |
| Janssen Products, LP | 1 | $108 |
| Halozyme Inc | 5 | $79 |
| Endo Pharmaceuticals Inc. | 4 | $59 |
| Madrigal Pharmaceuticals | 2 | $52 |
| Eisai Inc. | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Hologic Sales And Service, LLC | 2 | $38 |
| AbbVie | 2 | $36 |
| Tolmar, Inc. | 2 | $35 |
| Vertex | 1 | $31 |
| Exact Sciences | 1 | $29 |
| Almatica Pharma LLC | 1 | $28 |
| Pfizer | 1 | $20 |
| GSK | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Medtronic | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,020 in reported general payments places this provider in the 95th percentile of 804 surgical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 125 | $557,287 |
| CabenuvaCabotegravir/Rilpivirine | 42 | $289,998 |
| DescovyEmtricitabine/Tenofov Alafenam | 114 | $271,143 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 51 | $225,659 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 42 | $225,555 |
| JulucaDolutegravir/Rilpivirine | 35 | $139,779 |
| Egrifta SvTesamorelin Acetate | 19 | $139,183 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 26 | $126,412 |
| TivicayDolutegravir Sodium | 46 | $115,663 |
| IsentressRaltegravir Potassium | 37 | $75,605 |
| DovatoDolutegravir Sodium/Lamivudine | 22 | $67,126 |
| PrezcobixDarunavir/Cobicistat | 20 | $47,309 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 11 | $45,939 |
| MytesiCrofelemer | 12 | $30,992 |
| OzempicSemaglutide | 27 | $26,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya, Stribild, Tybost | $3,423 | $1,103,130312 claims |
| Viiv Healthcare CompanyCabenuva, Juluca, Tivicay, Dovato | $4,957 | $612,566145 claims |
| Janssen Products, LPSymtuza | $108 | $225,55542 claims |
| Theratechnologies Inc.Egrifta Sv | $1,189 | $139,18319 claims |
| MerckIsentress, Dulera | $772 | $79,84549 claims |
| Johnson & JohnsonPrezcobix | $167 | $47,30920 claims |
| Napo Pharmaceuticals IncMytesi | $897 | $30,99212 claims |
| Novo NordiskOzempic | $882 | $26,31927 claims |
| PfizerEliquis | $20 | $11,52212 claims |
| AstraZenecaBevespi Aerosphere | $319 | $4,67111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 surgical providers in Texas.
Other surgical in Houston
- Marilyn ShookHouston$46K
- Zeena PatelHouston$13K
- Lisa LauHouston$6K
- Paige WheatonHouston$5K
- Janelle JakobiHouston$5K
- Sana SiddiqiHouston$5K
- Angela LimmerHouston$5K
- Jacqueline Tavares-AlvaradoHouston$5K
- Tanner SteedHouston$4K
- Courtney DunavantAustin$389K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.